Wells Fargo & Company Talaris Therapeutics, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$2.68 - $3.22 $42 - $51	-16 Reduced 10.32%	139 $0
Q2 2023 Aug 15, 2023	SELL	$1.78 - $3.2 $7,002 - $12,588	-3,934 Reduced 96.21%	155 $0
Q1 2023 May 12, 2023	BUY	$1.09 - $2.09 $4,457 - $8,546	4,089 New	4,089 $7,000
Q3 2022 Nov 14, 2022	SELL	$2.3 - $5.03 $347 - $759	-151 Reduced 77.04%	45 $0
Q2 2022 Aug 12, 2022	SELL	$4.51 - $9.85 $2,444 - $5,338	-542 Reduced 73.44%	196 $1,000
Q1 2022 May 16, 2022	SELL	$6.89 - $16.56 $54,458 - $130,890	-7,904 Reduced 91.46%	738 $7,000
Q4 2021 Feb 14, 2022	BUY	$12.18 - $17.0 $105,259 - $146,914	8,642 New	8,642 $132,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.